Evidence map›Paper›PMID 36891725›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2022

[The role of circulating tumor DNA in the diagnosis and prognosis of hepatocellular carcinoma].

Z H Fan, F Ren

Open access · greenAbstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Z H FanBeijing Youan Hospital, Capital Medical University Beijing Institute of Heputology, Beijing 100069, China.
F RenBeijing Youan Hospital, Capital Medical University Beijing Institute of Heputology, Beijing 100069, China.
Beijing YouAn Hospital · CN

Funding

Beijing Natural Science Foundation and Beijing Municipal Education Commission Jointly Funded a Key Project KZ202010025035Beijing Science and Technology Program Special Project "Capital Clinical Diagnosis and Treatment Technology Research and Demonstration Application" Z191100006619096, Z191100006619097High-level Public Health Technical Personnel Construction Project Subject leaders-02-13Ministry of Science and Technology Major Disease Special Projects 2018ZX10301407-005-002, 2018ZX10302205-004-004National Natural Science Foundation of China 81770611Talent Cultivation plan of "Climbing the Peak" of Beijing Municipal Hospital Administration DFL20221503
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the common malignant tumors. However, the detection of biomarkers can't meet the clinical needs for the diagnosis and prognosis of HCC now. Circulating tumor DNA (ctDNA) is a highly tumor-specific DNA molecule that exists in the blood circulation. It is part of Circulating cell free DNA (cfDNA) and originates from the primary tumor or metastasis of cancer patients. Now, with the developing of next-generation sequencing technology and a full understanding of HCC genetics or epigenetic changes, we can analyze ctDNA mutations and methylation more comprehensively. Through continuous exploration of ctDNA mutations and methylation and continuous innovation of detection methods, HCC diagnosis and prognosis can be greatly improved in terms of specificity and sensitivity.

Indexed as

Carcinoma, HepatocellularCirculating Tumor DNALiver NeoplasmsBiomarkers, TumorDNAHumansMutationPrognosisBiomarkers, TumorCirculating Tumor DNADNA

Identifiers

PMID36891725
PMCPMC12825095
OpenAlexW4323652722

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.